QIHAN BIOTECH

Home About Us Science Newsroom Careers Contact

Press Releases

Dr. Luhan Yang Selected for the Inaugural Aspen Institute Technology Leaders Initiative Learn More

Qihan Biotech's QT-019B Receives FDA RMAT and BTD Learn More

Qihan Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially optimized low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases Learn More

Dr. Luhan Yang Selected for the Inaugural Aspen Institute Technology Leaders Initiative

Qihan Biotech today announced that its Co-Founder and Chief Executive Officer, Dr. Luhan Yang, has been selected for the Technology Leaders Initiative (TLI) of the Aspen Institute. Dr. Yang is one of 22 leaders chosen for the initiative’s inaugural global cohort.

Expanded Access Policy

Qihan Biotech's QT-019B Receives FDA RMAT and BTD

Qihan Biotech announced that its internally developed universal dual-target CAR-T therapy, QT-019B, has officially received both Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough Therapy Designation (BTD) from the U.S. FDA.

Qihan Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially optimized low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases

Qihan Biotech announced today that QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).

Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for Refractory Systemic Lupus Erythematosus

Qihan Biotech Presents New Clinical Data on Allogeneic CAR-T Cell Therapies and Preclinical Data on In Vivo CAR-T at the American Society of Hematology (ASH) Annual Meeting

Qihan Biotech presented an oral and several poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting.

Qihan Biotech Announces Multiple Presentations at the 2025 American Society of Hematology (ASH) Annual Meeting

At the upcoming 2025 ASH Annual Meeting, Qihan Biotech will present new data highlighting significant progress across its off-the-shelf and in vivo CAR-T cell therapy programs.

Qihan Biotech Announces FDA Clearance of IND for QT-019B, a Universal Dual-Target CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

The U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QT-019B.

iPSC-CAR-NK Cell Therapy Clinical Results Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment

Qihan Biotech announced the publication of groundbreaking clinical results in Cell.